Please assess the completion status of the following clinical trial:

Trial Title: Codeine Plus Paracetamol Versus Placebo for PRK Post-operative Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* older than 20 years~* spherical component between -1.00 and -5.00, with or without astigmatism~* cylindrical component up to 1.5D~* spherical anisometropia of less than or equal to 0.75D,~* cylindrical anisometropia of less than or equal to 0.5D,~* stable refraction errors (maximal variation of 0.5D in the spherical or cylindrical component during 1 year)~* amenable to follow-up for at least seven (7) days.~Exclusion Criteria:~* presence of active disease of allergic, inflammatory or infectious nature, in the ocular surface or its attachments~* previous ocular history (pathology, surgery or ocular trauma)~* best corrected visual acuity less than 20/25)~* autoimmune disease, or immunosuppression or Diabetes Mellitus~* pregnancy or lactation.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Codeine plus paracetamol (Type: ACTIVE_COMPARATOR): Codeine plus paracetamol every 6 hours for 72 hours after photorefractive keratectomy.
- placebo (Type: PLACEBO_COMPARATOR): Placebo every 6 hours for 72 hours after photorefractive keratectomy.

Based on this trial design, predict the completion outcome and termination type (if applicable).